Evidence map›Paper›PMID 26873702›Full record

Trial reportDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2016

[Development of serous retinopathy during therapy of a metastatic cutaneous melanoma].

I Lüdeke, P Terheyden, S Grisanti, M Lüke

Abstract readCase ReportsRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Toxic retinopathies].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Article
  2. [Tyrosine kinase inhibitor-associated choroidopathy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Article
  3. [Paraneoplastic serous retinopathies: hormones, mediators, and inhibitors].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

I LüdekeKlinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland. inger.luedeke@rwth-aachen.de.
P TerheydenHautkrebszentrum Lübeck, Klinik für Dermatologie, Allergologie und Venerologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Deutschland.
S GrisantiKlinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.
M LükeKlinik und Poliklinik für Augenheilkunde, Universitätsklinikum Schleswig Holstein, Campus Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of the mitogen-activated protein kinase (MAPK) signal pathway have decisively improved the prognosis of metastatic cutaneous melanoma in patients with an activating mutation in position V600 of the BRAF gene. We report on a patient who was regularly examined in our clinic while participating in a randomized blinded clinical trial. The aim of this trial was to examine the effectiveness and tolerability of a combination of the BRAF inhibitor dabrafenib and the MAPK kinase (MEK) inhibitor trametinib compared with a monotherapy with dabrafenib (plus placebo). During therapy the patient developed a diffuse neuroretinal detachment which could not be completely reversed after discontinuation of the study medication.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCentral Serous ChorioretinopathyDiagnosis, DifferentialFemaleHumansImidazolesMelanomaMiddle AgedOximesPyridonesPyrimidinonesSingle-Blind MethodSkin NeoplasmsTreatment OutcomedabrafenibImidazolesOximesPyridonesPyrimidinonestrametinibBRAF inhibitorChorioretinopathyDabrafenibMEK inhibitorTrametinib

Identifiers

PMID26873702

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.